AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
ProMIS Neurosciences, Inc.
Video analysis: PMN
All videosNo video analysis for this stock yet. Request one from our team.
News: PMN
ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September
CAMBRIDGE, Mass, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming September 2026 conferences and key investor events, and will be available for one-on-one meetings.
Promis Neurosciences Q2 Earnings Call Highlights
Promis Neurosciences NASDAQ: PMN reported second-quarter 2026 results and highlighted blinded six-month interim data from its Phase 1b PRECISE-AD study of PMN310, an investigational antibody for early Alzheimer's disease.
ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights
Cambridge, Massachusetts, Aug. 13, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced its financial results for the quarter ended June 30, 2026, and provided a corporate update.
Vertex Pharmaceuticals Inc (VRTX) (Q2 2026) Earnings Call Highlights: Revenue Surges 12% to $3.3 Billion, Driven by CF Portfolio and New Product Momentum
Total Revenue: $3.3 billion in Q2 2026, up 12% year-over-year.CF Revenue: Global CF revenue grew 11% year-over-year in Q2 2026.CASGEVY Revenue: $76 million in Q
ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026
Company to host investor conference call and webcast at 4:30 p.m. ET. Cambridge, Massachusetts, Aug. 03, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced it will report financial results for the second quarter ended June 30, 2026, and provide corporate updates on August 13, 2026.
ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026
Company to host investor conference call and webcast at 4:30 p. m. ET. Cambridge, Massachusetts, Aug. 03, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc.
Promis Reports No ARIA-E in PMN310 Alzheimer's Trial Interim Data
Promis Neurosciences NASDAQ: PMN reported blinded six-month interim data from its Phase 1b PRECISE-AD trial of PMN310, an investigational antibody designed to selectively target toxic amyloid-beta oligomers in patients with mild cognitive impairment due to Alzheimer's disease and early Alzheimer's disease.
Small-Cap ProMIS Neurosciences Says Lead Drug Shows Encouraging Action in Early Alzheimer's Study
ProMIS Neurosciences Inc. (NASDAQ:PMN) reported positive blinded six-month interim safety and biomarker results from its ongoing Phase 1b PRECISE-AD trial evaluating lead drug candidate PMN310 in patients with mild cognitive impairment due to Alzheimer's disease.
